Modification Makes Immunotherapy for Blood Cancer Even More Effective

Modification makes immunotherapy for blood cancer even more effective

Currently, half of patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia—two types of cancer that affect blood cells—do not respond adequately to treatment with CAR-T cells. The therapy involves harvesting the patient's own defense cells (T lymphocytes), modifying them in the laboratory to make them capable of destroying tumor cells, and reinjecting them into the body. These refractory cases usually relapse after conventional imm…

Enhanced Modification Boosts Immunotherapy Effectiveness Against Blood

In the evolving landscape of cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a beacon of hope, particularly in hematological malignancies such as non-Hodgkin’s lymphoma and acute lymphoblastic leukemia. Despite its groundbreaking potential, approximately fifty percent of patients afflicted with these blood cancers exhibit resistance or an inadequate response to the current CAR-T cell treatments. This significant…